InterMune Company Profile (NASDAQ:ITMN)

About InterMune

InterMune logoInterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ITMN
  • CUSIP: 45884X10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -55.56
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to InterMune:

Analyst Ratings

Consensus Ratings for InterMune (NASDAQ:ITMN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for InterMune (NASDAQ:ITMN)
No equities research coverage for this company has been tracked by


Earnings History for InterMune (NASDAQ:ITMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2014Q214($0.56)($0.72)$33.96 million$35.70 millionViewListenView Earnings Details
5/1/2014Q114($0.62)($0.59)$28.24 million$30.30 millionViewListenView Earnings Details
10/30/2013Q313($0.71)($0.61)$16.44 million$19.72 millionViewListenView Earnings Details
7/24/2013Q2 2013($0.70)($0.77)$12.95 million$14.40 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.73)($0.64)$10.53 million$10.53 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.87)($0.90)$8.31 million$8.20 millionViewListenView Earnings Details
11/7/2012Q312($0.83)($0.70)$6.31 million$7.50 millionViewN/AView Earnings Details
7/23/2012$0.10$0.01ViewN/AView Earnings Details
4/26/2012($0.70)($0.74)ViewN/AView Earnings Details
2/9/2012($0.71)($0.69)ViewN/AView Earnings Details
11/3/2011($0.72)($0.63)ViewN/AView Earnings Details
8/4/2011($0.62)($0.68)ViewN/AView Earnings Details
4/28/2011($0.78)($0.57)ViewN/AView Earnings Details
2/16/2011$0.64$3.34ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for InterMune (NASDAQ:ITMN)
Current Year EPS Consensus Estimate: $-2.74 EPS
Next Year EPS Consensus Estimate: $-1.33 EPS


Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for InterMune (NASDAQ:ITMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2014Andrew Kenneth William PowellEVPSell7,500$73.47$551,025.00View SEC Filing  
8/13/2014Paul D ArataEVPSell7,500$50.00$375,000.00View SEC Filing  
8/11/2014John HodgmanCFOSell4,724$43.05$203,368.20View SEC Filing  
8/7/2014Daniel G WelchCEOSell171,025$44.98$7,692,704.50View SEC Filing  
7/17/2014Paul D ArataEVPSell2,382$41.00$97,662.00View SEC Filing  
7/15/2014Jonathan A LeffEVPSell35,000$43.08$1,507,800.00View SEC Filing  
6/18/2014Sean P NolanEVPSell10,000$47.10$471,000.00View SEC Filing  
6/16/2014Daniel G WelchCEOSell15,000$45.02$675,300.00View SEC Filing  
6/13/2014Sean P NolanEVPSell20,000$42.80$856,000.00View SEC Filing  
6/4/2014Daniel G WelchCEOSell3,914$39.19$153,389.66View SEC Filing  
6/3/2014John HodgmanCFOSell1,201$38.78$46,574.78View SEC Filing  
6/3/2014Jonathan A LeffEVPSell1,153$38.78$44,713.34View SEC Filing  
5/30/2014Daniel G WelchCEOSell4,565$40.06$182,873.90View SEC Filing  
5/29/2014David S KabakoffDirectorSell5,000$39.56$197,800.00View SEC Filing  
5/27/2014Daniel G WelchCEOSell41,493$40.03$1,660,964.79View SEC Filing  
5/19/2014Sean NolanEVPSell7,500$39.50$296,250.00View SEC Filing  
5/8/2014Sean NolanVPSell2,644$35.85$94,787.40View SEC Filing  
5/6/2014Daniel WelchCEOSell60,432$34.76$2,100,616.32View SEC Filing  
3/4/2014Jonathan LeffEVPSell27,361$30.95$846,822.95View SEC Filing  
3/4/2014Nepi Giacomo DiDirectorSell70,000$30.84$2,158,800.00View SEC Filing  
1/10/2014Daniel WelchCEOSell50,000$17.00$850,000.00View SEC Filing  
12/2/2013Daniel WelchCEOSell20,000$13.99$279,800.00View SEC Filing  
10/1/2013Daniel G WelchCEOSell70,000$15.43$1,080,100.00View SEC Filing  
8/30/2013David KabakoffDirectorSell10,002$14.82$148,229.64View SEC Filing  
8/27/2013Angus RussellDirectorBuy6,600$14.53$95,898.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for InterMune (NASDAQ:ITMN)
DateHeadline logoEx-InterMune executive, friend found liable for insider trading (NASDAQ:ITMN) - November 14 at 5:56 PM
News IconIndigenous Liberal MP breaks with his government over B.C. hydro dam support (NASDAQ:ITMN) - September 15 at 6:08 PM
News IconChinese actress' death sparks cancer treatment debate (NASDAQ:ITMN) - September 15 at 6:08 PM logoYour jet-black iPhone 7 might not look new for long (NASDAQ:ITMN) - September 15 at 6:08 PM
News IconPresident Obama creates an 'underwater Yellowstone' with first US national monument in the Atlantic Ocean (NASDAQ:ITMN) - September 15 at 6:08 PM logoThe Push and Pull of Gender for Muslims at the Hajj (NASDAQ:ITMN) - September 15 at 6:08 PM logoNetflix's 'White Helmets' Highlights a Syrian Rescue Group on the Front Line (NASDAQ:ITMN) - September 15 at 6:08 PM logoIndians, Some Seeking Brighter Fortunes, Celebrate Vibrant Ganesh Festival (NASDAQ:ITMN) - September 15 at 6:08 PM
News IconChicago lakefront golf project could involve Tiger Woods (NASDAQ:ITMN) - September 15 at 6:08 PM
News IconExpansion plan for Ottawa’s historic Chateau Laurier sparks social media backlash (NASDAQ:ITMN) - September 15 at 6:08 PM
News IconU.S. regulators recall 1M Samsung smartphones due to fire hazard (NASDAQ:ITMN) - September 15 at 6:08 PM logoRoche's $8 billion InterMune buy not a signal for more big deals (NASDAQ:ITMN) - September 16 at 12:55 PM logoInterMune drug may offer big upside to Roche if aimed at liver (NASDAQ:ITMN) - August 27 at 5:58 PM logoUS STOCKS-Futures point to higher open; S&P 500 near record (NASDAQ:ITMN) - August 25 at 8:51 AM logoUS STOCKS-Futures rise on hopes for ECB action, merger activity (NASDAQ:ITMN) - August 25 at 7:22 AM logoRoche to buy California biotech firm InterMune for $8.3 billion (NASDAQ:ITMN) - August 24 at 7:29 PM logoRoche to buy U.S. biotech firm InterMune for $8.3 billion (NASDAQ:ITMN) - August 24 at 4:52 PM logoRoche to buy U.S. biotech firm InterMune for $8.3 bln (NASDAQ:ITMN) - August 24 at 2:20 PM logoRoche to buy US biotech firm InterMune for $8.3B (NASDAQ:ITMN) - August 24 at 1:19 PM logoInterMune taps banks as it braces for buyout bids -sources (NASDAQ:ITMN) - August 13 at 1:13 PM


What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

How do I buy InterMune stock?

Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of InterMune stock cost?

One share of InterMune stock can currently be purchased for approximately $73.89.

InterMune (NASDAQ:ITMN) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for InterMune (NASDAQ:ITMN)

Earnings History Chart

Earnings by Quarter for InterMune (NASDAQ:ITMN)

Dividend History Chart

Dividend Payments by Quarter for InterMune (NASDAQ:ITMN)

Last Updated on 2/24/2017 by Staff